Traws Pharma Financial Results
Traws Pharma reported Q3 2026 financial results and provided clinical updates for its COVID-19 and influenza antiviral programs. The company highlighted positive Phase 2a results for ratutrelvir and plans to engage the FDA on a registration strategy for PAXLOVID-ineligible patients.
- Term
- Q3 2026
“We have made meaningful progress toward our goal of developing new treatment and prevention options for patients most vulnerable to serious respiratory viral diseases.”
Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma
“For tivoxavir marboxil, the tablet bridging study achieved its objectives, and toxicology retesting is complete. These results support further evaluation of TXM as a potential once-monthly oral influenza prevention option. We expect to resubmit the updated toxicology package in the fourth quarter.”
Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma